FDA Brief: Week of Mar 7, 2016

 

FDA Voice

 

‘Leaning in’ on Combination Products

By:

Nina L. Hunter, Ph.D.,  Associate Director for Science Policy in the Office of Medical Products and Tobacco

Rachel E. Sherman, M.D., M.P.H., Associate Deputy Commissioner in the Office of Medical Products and Tobacco

Combination Products:

  • Combine drugs, devices, and/or biological products
  • Include components from multiple regulatory categories (e.g., drug and device, drug and biologic, biologic and device, drug, device, and biologic) with distinct regulatory requirements
  • Review requires involvement of more than one FDA Center
  • Present regulatory, policy, and review management challenges

FDA Approach:

  • Improve overall efficiency, consistency, and predictability of combination product review
  • Launch Lean Management Process Mapping

Expected Outputs:

  • Baseline Map on existing sources of delay or redundancy
  • Identify metrics for success and to assess the impact of improvements
  • Future Map  on streamlined, efficient process that will eliminate previously identified delays and redundancies
  • Reflect FDA’s prior success with Lean Management

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s